Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash from Operations (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Cash from Operations for 4 consecutive years, with 14149000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 52.85% to 14149000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 103757000.0 through Dec 2025, down 32.83% year-over-year, with the annual reading at 103757000.0 for FY2025, 32.83% down from the prior year.
  • Cash from Operations for Q4 2025 was 14149000.0 at Day One Biopharmaceuticals, down from 5805000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 50753000.0 in Q3 2024, with the low at 58997000.0 in Q1 2025.
  • Average Cash from Operations over 4 years is 27412312.5, with a median of 29897500.0 recorded in 2022.
  • The sharpest move saw Cash from Operations soared 236.93% in 2024, then tumbled 111.44% in 2025.
  • Over 4 years, Cash from Operations stood at 35310000.0 in 2022, then dropped by 17.17% to 41372000.0 in 2023, then increased by 27.47% to 30008000.0 in 2024, then soared by 52.85% to 14149000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 14149000.0, 5805000.0, and 24806000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.